Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific...
Reexamination Certificate
2003-10-27
2010-11-02
Le, Emily M. (Department: 1648)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
Reexamination Certificate
active
07824696
ABSTRACT:
The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
REFERENCES:
patent: 5149798 (1992-09-01), Agrawal et al.
patent: 6815429 (2004-11-01), Agrawal
patent: WO99/62923 (1999-12-01), None
patent: WO 99/62923 (1999-12-01), None
Zhao et al. Immunostimulatory Activity of CpG containing phosphorothioate oligodeoxynucleotide in modulated by modification of a single deoxynucleoside. Bioorganic and Medicinal Chemistry Letters, May 15, 2000, vol. 10, 1051-1054.
Nguyen et al. Modification of DNA duplexes to smooth their thermal stability independently of their base content for DNA sequencing by hybridization. Nucleic Acids Research, 1997, vol. 25, No. 15, 3059-3065.
Peyrottes et al. Oligodeoxynucleoside phosphoramidates (P-NH 2 ): synthesis and thermal stability of duplexes with DNA and RNA targets. Nucleic Acids Research, 1996, vol. 24, No. 10, 1841-1848.
Khorana et al. (1972) “Studies on Polynucleotides,”J. Molec. Biol. 72:209.
Reese (1978) “The Chemical Synthesis of Oligo- and Poly-Nucleotides by the Phosporotriester Approach,”Tetrahedron34:3143-3179.
Beaucage et al. (1981) “Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for Deoxypolynucleotide Synthesis,”Tetrahedron Lett. 22:1859-1862.
Connolly et al. (1984) “Synthesis and Characterization of an Octanucledide Containing theEcoRI Recognition Sequence With A Phosphorothloate Group At The Cleavage Site,” Biochemistry 23:3443.
Agrawal et al. (1987) “Oligodeoxynucleotise Methylphosphonates: Synthesis and Enzymic Degradation,”Tetrahedron Lett. 28(31):3539-3542.
Jager et al. (1988) OligonucleotideN-Alkylphosphoroamidates: Synthesis and Binding to Polynucleotides,Biochemistry27:7237.
Agrawal et al. (1988) Oligodeoxynucleoside Phosphoroamidates and Phosporothloates As Inhibitors of Human Immunodefidency Virus,Proc. Natl. Acad. Scl. USA85:7079-7083.
Zon et al. (1991) “Phosphorothioate Oligonculeotides”Oligonucleotides and Analogues: A Practical Approachpp. 87-108.
Kuramoto et al. (1992) “Oligonucleotide Sequences Required For Natural Killer Cell Activation,”Jpn. J. Cancer Res. 83:1128-1131.
Crooke (1993) “An Overview of Progress in Antisense Therapeutics,” 8Antisense&Nucl. Acid Drug Dev. 115-122 CRC Press, Boca Raton, Florida.
Zon (1993) “Protocols for Oliognucleotides and Analogs,”Methods in Molecular Biologyvol. 20, pp. 165-189.
Pisetsky et al. (1994)“Stimulation of Murine Lymphocyte Proliferation By A Phosphorothioate Oligonucleotide With Antisense Activity For Herpes Simplex Virus,” 54Life Sci. 101.
Yamamoto et al. (1994) “Lipofection of Synthetic Oligodeoxyribonucleotide Having a Palindromic Sequence of AACGTT to Murine Spenocytes Enhances Interferon Production and Natural Killer Activity,” 38Microbiol. Immunol. 831.
Agrawal et al. (1995) “Modified Oligonucleotides as Therapeutic and Diagnostic Agents,”Curr.Opin.Biotechnol. 6:12-19.
Krieg et al. (1995) “CpG Motifs In Bacterial DNA Trigger Direct B-Cell Activation,”Nature371:546-549.
Klinman et al. (1996) “CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6, Interleukin 12, and Interferon γ,” 93Proc. Natl. Acad. Sci. USA2879.
Liang et al. (1996) “Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides,”J. Clin. Invest.98:1119-1129.
Zhao et al. (1996) “Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation,”Biochem. Pharm. 51:173-182.
Chu et al. (1997) “CpG Oligodeoxynucleotides Act As Adjuvants That Switch On T Helper 1 (Th1) Immunity,” 186J. Exp. Med.1623.
Dunford et al. (1997) “Antisense 97: Targeting the Molecular Basis of Disease” (Nature Biotechnology)Conference Abstract, pp. 40.
Sparwasser et al. (1997) “Macorphages Sense Pathogens Via DNA Motifs: Induction of Tumor Necrosis Factor-α-Mediated Shock,” 27Eur. J. Immunol. 1671.
Zhao et al. (1997) “Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Oligonucleotides in Mice,” 7Antisense Nucleic Acid Drug. Dev.495.
McCluskie et al. (1998) “Cutting Edge: CpG DNA Is A Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice,”J. Immunol. 161:4463-4466.
Moldoveanu et al. (1998) “CpG DNA, A Novel Immune Enhancer for Systemic and Mucosal Immunization With Influenza Virus,”Vaccine16:1216-1224.
Sparwasser et al. (1998) “Bacterial DNA and Immunostimulatory CpG Oligonucleotides Trigger Maturation and ACtivation of Murine Dendritic Cells,” 28Eur. J. Immunol. 2045.
Tokunaga et al. (1999) “How BCG Led to the Discovery of Immunostimulatory DNA,” 52Jap. J. Infect. Dis. 1.
Zhao et al. (1999) “Site of Chemical Modifications in CpG Containning Phosphorothioate Oligodeoxynucleotide Modulates its Immunostimulatory Activity,”Bioorg. &Med. Chem. Lett. 9:3453-3458.
Agrawal et al. (2000) “Antisense Therapeutics: Is It As Simple As Complementary Base Recognition,” 6Mol. Med. Today72.
Zhao et al. (2000) “Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside,”Bioorg. &Med. Chem. Lett. 10:1051-1054.
Agrawal et al., “Antisense therapeutics”, Curr. Opin. Chem. Biol., 2:519-528, 1998.
Chaix et al., “3′-3′ Linked Oligonucleotides:Synthesis and Stability Studies”, Biorg. & Med. Chem., 6:827-832, 1996.
Klinman, “therapeutic Applications of CpG-Containing Oli-Godeoxynucleotides”, Antisense & Nucl. Acid Drug Dev., 8:181-184, 1998.
Yu et al., “Accessible 5′-End of CpG-Containing . . . ”, Bioorganic & Medicianl Chemistry Lett., 10:2585-2588, 2000.
Kandimalla et al., “Effect of Chemical Modifications . . . ”, Bioorganic & Medicinal Chemistry, 9:807-813, 2001.
International Search Report (PCT App. No. PCT/US01/30137).
Agrawal Sudhir
Kandimalla Ekambar R.
Yu Dong
Zhao Qiuyan
Idera Pharmaceuticals Inc.
Keown Wayne A.
Le Emily M.
Preti Flaherty
LandOfFree
Modulation of immunostimulatory activity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of immunostimulatory activity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of immunostimulatory activity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4192769